{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:10:36Z","timestamp":1793725836435,"version":"4.6.1"},"reference-count":25,"publisher":"Pacini Editore","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Otorhinolaryngol Ital"],"DOI":"10.14639\/0392-100x-n2156","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T11:01:21Z","timestamp":1673866881000},"page":"538-544","source":"Crossref","is-referenced-by-count":20,"title":["A prospective study on the efficacy of dupilumab in chronic rhinosinusitis with type 2 inflammation","Studio prospettico sull\u2019efficacia di dupilumab per rinosinusite cronica con infiammazione di tipo 2"],"prefix":"10.14639","volume":"42","author":[{"given":"Matteo","family":"Trimarchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Vinciguerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rampi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Tanzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Nonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona Rita","family":"Yacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Bussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"20340","published-online":{"date-parts":[[2022,12]]},"reference":[{"key":"10.14639\/0392-100X-N2156_ref1","doi-asserted-by":"crossref","unstructured":"Scangas GA, Wu AW, Ting JY, et al. Cost utility analysis of dupilumab versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps. Laryngoscope 2021;131:e26-e33. https:\/\/doi.org\/10.1002\/lary.28648","DOI":"10.1002\/lary.28648"},{"key":"10.14639\/0392-100X-N2156_ref2","doi-asserted-by":"crossref","unstructured":"Fokkens WJ, Lund VJ, Mullol J, et al. 2012 EPOS 2012 European position paper on rhinosinusitis and nasal polyps. Rhinology 2012;50:1-12. https:\/\/doi.org\/10.4193\/Rhino12.000","DOI":"10.4193\/Rhino50E2"},{"key":"10.14639\/0392-100X-N2156_ref3","doi-asserted-by":"crossref","unstructured":"Stevens WW, Schleimer RP, Kern RC. Chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract 2016;4:565-572. https:\/\/doi.org\/10.1016\/j.jaip.2016.04.012","DOI":"10.1016\/j.jaip.2016.04.012"},{"key":"10.14639\/0392-100X-N2156_ref4","doi-asserted-by":"crossref","unstructured":"Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology 2020;58(Suppl S29):1-464. https:\/\/doi.org\/10.4193\/Rhin20.600","DOI":"10.4193\/Rhin20.600"},{"key":"10.14639\/0392-100X-N2156_ref5","doi-asserted-by":"crossref","unstructured":"Yacoub MR, Trimarchi M, Cremona G, et al. Are atopy and eosinophilic bronchial inflammation associated with relapsing forms of chronic rhinosinusitis with nasal polyps? Clin Mol Allergy 2015;13:23. https:\/\/doi.org\/10.1186\/s12948-015-0026-8","DOI":"10.1186\/s12948-015-0026-8"},{"key":"10.14639\/0392-100X-N2156_ref6","doi-asserted-by":"crossref","unstructured":"Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 2019;394:1638-1650. https:\/\/doi.org\/10.1016\/S0140-6736(19)31881-1","DOI":"10.1016\/S0140-6736(19)31881-1"},{"key":"10.14639\/0392-100X-N2156_ref7","doi-asserted-by":"crossref","unstructured":"van der Lans RJL, Fokkens WJ, Adriaensen GFJPM, et al. Real-life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps. Allergy 2022;77:670-674. https:\/\/doi.org\/10.1111\/all.15134","DOI":"10.1111\/all.15134"},{"key":"10.14639\/0392-100X-N2156_ref8","doi-asserted-by":"crossref","unstructured":"Gallo S, Russo F, Mozzanica F, et al. Prognostic value of the sinonasal outcome test 22 (SNOT-22) in chronic rhinosinusitis. Acta Otorhinolaryngol Ital 2020;40:113-121. https:\/\/doi.org\/10.14639\/0392-100X-N0364","DOI":"10.14639\/0392-100X-N0364"},{"key":"10.14639\/0392-100X-N2156_ref9","doi-asserted-by":"crossref","unstructured":"Ninan S, Goldrich DY, Liu K, et al. Long term olfactory outcomes following frontal sinus surgery in chronic rhinosinusitis. Laryngoscope 2021;131:2173-2178. https:\/\/doi.org\/10.1002\/lary.29513","DOI":"10.1002\/lary.29513"},{"key":"10.14639\/0392-100X-N2156_ref10","doi-asserted-by":"crossref","unstructured":"Van Dijk BCP, Svedsater H, Heddini A, et al. Relationship between the Asthma Control Test (ACT) and other outcomes: a targeted literature review. BMC Pulm Med 2020;20:79 https:\/\/doi.org\/10.1186\/s12890-020-1090-5","DOI":"10.1186\/s12890-020-1090-5"},{"key":"10.14639\/0392-100X-N2156_ref11","doi-asserted-by":"crossref","unstructured":"DeConde AS, Bodner TE, Mace JC, et al. Development of a clinically relevant endoscopic grading system for chronic rhinosinusitis using canonical correlation analysis. Int Forum Allergy Rhinol 2016;6:478-485. https:\/\/doi.org\/10.1002\/alr.21683","DOI":"10.1002\/alr.21683"},{"key":"10.14639\/0392-100X-N2156_ref12","doi-asserted-by":"crossref","unstructured":"Lund VJ, Kennedy DW. Staging for rhinosinusitis. Otolaryngol Head Neck Surg 1997;117(3 Pt 2):S35-S40. https:\/\/doi.org\/10.1016\/s0194-5998(97)70005-6","DOI":"10.1016\/S0194-5998(97)70005-6"},{"key":"10.14639\/0392-100X-N2156_ref13","doi-asserted-by":"crossref","unstructured":"Vaira LA, Hopkins C, Petrocelli M, et al. The Amsterdam Classification of Completeness of Endoscopic Sinus Surgery (ACCESS): a new CT-based scoring system grading the extent of surgery. Rhinology 2020;58:538-543. https:\/\/doi.org\/10.4193\/Rhin20.165","DOI":"10.4193\/Rhin20.165"},{"key":"10.14639\/0392-100X-N2156_ref14","doi-asserted-by":"crossref","unstructured":"Vinciguerra A, Rampi A, Yacoub MR, et al. Hypereosinophilia management in patients with type 2 chronic rhinosinusitis treated with dupilumab: preliminary results. Eur Arch Otorhinolaryngol 2022;279:5231-5238. https:\/\/doi.org\/10.1007\/s00405-022-07389-5","DOI":"10.1007\/s00405-022-07389-5"},{"key":"10.14639\/0392-100X-N2156_ref15","doi-asserted-by":"crossref","unstructured":"Naclerio R, Baroody F, Bachert C, et al. Clinical research needs for the management of chronic rhinosinusitis with nasal polyps in the new era of biologics: a national institute of allergy and infectious diseases workshop. J Allergy Clin Immunol Pract 2020;8:1532-1549. https:\/\/doi.org\/10.1016\/j.jaip.2020.02.023","DOI":"10.1016\/j.jaip.2020.02.023"},{"key":"10.14639\/0392-100X-N2156_ref16","doi-asserted-by":"crossref","unstructured":"De Corso E, Settimi S, Montuori C, et al. Effectiveness of dupilumab in the treatment of patients with severe uncontrolled CRSwNP: A \u201cReal-Life\u201d observational study in the first year of treatment. J Clin Med 2022;11:2684. https:\/\/ doi.org\/10.3390\/jcm11102684","DOI":"10.3390\/jcm11102684"},{"key":"10.14639\/0392-100X-N2156_ref17","doi-asserted-by":"crossref","unstructured":"Trimarchi M, Indelicato P, Vinciguerra A, et al. Clinical efficacy of dupilumab in the treatment of severe chronic rhinosinusitis: the first case outside of a clinical trial. Clin Case Rep 2021;9:1428-1432. https:\/\/doi.org\/10.1002\/ccr3.3792","DOI":"10.1002\/ccr3.3792"},{"key":"10.14639\/0392-100X-N2156_ref18","doi-asserted-by":"crossref","unstructured":"Rombaux P, Huart C, Levie P, et al. Olfaction in chronic rhinosinusitis. Curr Allergy Asthma Rep 2016;16:41. https:\/\/doi.org\/10.1007\/s11882-016-0617-6","DOI":"10.1007\/s11882-016-0617-6"},{"key":"10.14639\/0392-100X-N2156_ref19","doi-asserted-by":"crossref","unstructured":"De Corso E, Bellocchi G, De Benedetto M, et al. Biologics for severe uncontrolled chronic rhinosinusitis with nasal polyps: a change management approach. Consensus of the Joint Committee of Italian Society of Otorhinolaryngology on biologics in rhinology. Acta Otorhinolaryngol Ital 2022;42:1-16 https:\/\/doi.org\/10.14639\/0392-100X-N1614","DOI":"10.14639\/0392-100X-N1614"},{"key":"10.14639\/0392-100X-N2156_ref20","doi-asserted-by":"crossref","unstructured":"Wollenberg A, Beck LA, Blauvelt A, et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol 2020;182:1120-1135. https:\/\/doi.org\/10.1111\/bjd.18434","DOI":"10.1111\/bjd.18434"},{"key":"10.14639\/0392-100X-N2156_ref21","doi-asserted-by":"crossref","unstructured":"Brown WC, Senior B. A critical look at the efficacy and costs of biologic therapy for chronic rhinosinusitis with nasal polyposis. Curr Allergy Asthma Rep 2020;20:16. https:\/\/doi.org\/10.1007\/s11882-020-00910-y","DOI":"10.1007\/s11882-020-00910-y"},{"key":"10.14639\/0392-100X-N2156_ref22","doi-asserted-by":"crossref","unstructured":"Kim J, Naclerio R. Therapeutic potential of dupilumab in the treatment of chronic rhinosinusitis with nasal polyps: evidence to date. Ther Clin Risk Manag 2020;16:31-37. https:\/\/doi.org\/10.2147\/TCRM.S210648","DOI":"10.2147\/TCRM.S210648"},{"key":"10.14639\/0392-100X-N2156_ref23","doi-asserted-by":"crossref","unstructured":"Lee Y, Kim ME, Nahm DH. Real clinical practice data of monthly dupilumab therapy in adult patients with moderate-to-severe atopic dermatitis: clinical efficacy and predictive markers for a favorable clinical response. Allergy Asthma Immunol Res 2021;13:733-745. https:\/\/doi.org\/10.4168\/aair.2021.13.5.733","DOI":"10.4168\/aair.2021.13.5.733"},{"key":"10.14639\/0392-100X-N2156_ref24","doi-asserted-by":"crossref","unstructured":"Brooks GD. Updated evaluation of dupilumab in the treatment of asthma: Patient selection and reported outcomes. Ther Clin Risk Manag 2020;16:181-187. https:\/\/doi.org\/10.2147\/TCRM.S192392","DOI":"10.2147\/TCRM.S192392"},{"key":"10.14639\/0392-100X-N2156_ref25","doi-asserted-by":"crossref","unstructured":"Rampi A, Vinciguerra A, Tanzini U, et al. Comparison of guidelines for prescription and follow-up of biologics for chronic rhinosinusitis with nasal polyps. Eur Arch Otorhinolayngol 2022. https:\/\/doi.org\/10.1007\/s00405-022-07634-x","DOI":"10.1007\/s00405-022-07634-x"}],"container-title":["Acta Otorhinolaryngologica Italica"],"original-title":[],"link":[{"URL":"https:\/\/www.actaitalica.it\/article\/view\/2156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T07:20:50Z","timestamp":1729668050000},"score":1,"resource":{"primary":{"URL":"https:\/\/old.actaitalica.it\/article\/view\/2156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,12]]}},"URL":"https:\/\/doi.org\/10.14639\/0392-100x-n2156","relation":{},"ISSN":["1827-675X"],"issn-type":[{"value":"1827-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]},"article-number":"6"}}